These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35882111)

  • 1. Development of a synthetic nanoparticle vaccine presenting the HIV-1 envelope glycoprotein.
    Ximba P; Chapman R; Meyers A; Margolin E; van Diepen MT; Sander AF; Woodward J; Moore PL; Williamson AL; Rybicki EP
    Nanotechnology; 2022 Sep; 33(48):. PubMed ID: 35882111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
    van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies.
    Malebo K; Woodward J; Ximba P; Mkhize Q; Cingo S; Moyo-Gwete T; Moore PL; Williamson AL; Chapman R
    Vaccines (Basel); 2024 Sep; 12(9):. PubMed ID: 39340093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.
    Ringe RP; Ozorowski G; Yasmeen A; Cupo A; Cruz Portillo VM; Pugach P; Golabek M; Rantalainen K; Holden LG; Cottrell CA; Wilson IA; Sanders RW; Ward AB; Klasse PJ; Moore JP
    J Virol; 2017 Jun; 91(12):. PubMed ID: 28381572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.
    Pugach P; Ozorowski G; Cupo A; Ringe R; Yasmeen A; de Val N; Derking R; Kim HJ; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; Julien JP; Burton DR; Wilson IA; Sanders RW; Klasse PJ; Ward AB; Moore JP
    J Virol; 2015 Mar; 89(6):3380-95. PubMed ID: 25589637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
    Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
    Sanders RW; Derking R; Cupo A; Julien JP; Yasmeen A; de Val N; Kim HJ; Blattner C; de la Peña AT; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; van Gils MJ; King CR; Wilson IA; Ward AB; Klasse PJ; Moore JP
    PLoS Pathog; 2013 Sep; 9(9):e1003618. PubMed ID: 24068931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers.
    Morris CD; Azadnia P; de Val N; Vora N; Honda A; Giang E; Saye-Francisco K; Cheng Y; Lin X; Mann CJ; Tang J; Sok D; Burton DR; Law M; Ward AB; He L; Zhu J
    mBio; 2017 Feb; 8(1):. PubMed ID: 28246356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Well-ordered trimeric HIV-1 subtype B and C soluble spike mimetics generated by negative selection display native-like properties.
    Guenaga J; de Val N; Tran K; Feng Y; Satchwell K; Ward AB; Wyatt RT
    PLoS Pathog; 2015 Jan; 11(1):e1004570. PubMed ID: 25569572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M; Hu K; Hu H; Ni F; Du T; Shattock RJ; Hu Q
    Vaccine; 2019 Dec; 37(51):7501-7508. PubMed ID: 31564450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.
    Ringe RP; Yasmeen A; Ozorowski G; Go EP; Pritchard LK; Guttman M; Ketas TA; Cottrell CA; Wilson IA; Sanders RW; Cupo A; Crispin M; Lee KK; Desaire H; Ward AB; Klasse PJ; Moore JP
    J Virol; 2015 Dec; 89(23):12189-210. PubMed ID: 26311893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.
    Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H
    J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256.
    van Diepen MT; Chapman R; Moore PL; Margolin E; Hermanus T; Morris L; Ximba P; Rybicki EP; Williamson AL
    PLoS One; 2018; 13(12):e0208310. PubMed ID: 30557314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
    Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.
    Torrents de la Peña A; de Taeye SW; Sliepen K; LaBranche CC; Burger JA; Schermer EE; Montefiori DC; Moore JP; Klasse PJ; Sanders RW
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29367243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies.
    Bale S; Martiné A; Wilson R; Behrens AJ; Le Fourn V; de Val N; Sharma SK; Tran K; Torres JL; Girod PA; Ward AB; Crispin M; Wyatt RT
    Front Immunol; 2018; 9():1116. PubMed ID: 29881382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.